Why Is Zimmer (ZBH) Down 2% Since Last Earnings Report?

Core Viewpoint - Zimmer Biomet's recent earnings report shows a mixed performance with adjusted earnings per share beating estimates, while overall revenue growth indicates a positive trend despite some margin contraction [2][4][8]. Financial Performance - The fourth-quarter adjusted earnings per share was $2.42, exceeding the Zacks Consensus Estimate by 1.7% and reflecting a year-over-year increase of 4.8% [2]. - Full-year adjusted earnings per share reached $8.20, marking a 2.5% increase year over year and slightly beating the Zacks Consensus Estimate by 0.5% [3]. - Net sales for the fourth quarter were $2.24 billion, a 10.9% increase year over year, surpassing the Zacks Consensus Estimate by 1.9% [4]. - Full-year net sales totaled $8.23 billion, up 7.2% year over year, also marginally exceeding the Zacks Consensus Estimate by 0.5% [4]. Revenue Breakdown - U.S. sales for the fourth quarter amounted to $1.31 billion, reflecting an 11.11% year-over-year increase, while international sales were $931.2 million, up 10.6% year over year [5]. - Sales in the Knees segment improved by 8.6% year over year to $911 million, while Hips sales grew by 6.8% to $555.4 million. The S.E.T. unit saw a significant rise of 20.1% to $587.6 million [6]. Margin Analysis - Adjusted gross margin was 64.7%, down 632 basis points year over year, primarily due to a 35.1% increase in the cost of products sold [8]. - Selling, general, and administrative expenses rose by 16.8% to $872.3 million, while research and development expenses increased by 9.6% to $118.8 million [8]. - Adjusted operating margin contracted by 821 basis points to 20.5% [8]. Cash Position - At the end of the fourth quarter, cash and cash equivalents stood at $591.9 million, up from $525.5 million at the end of the previous year [9]. - Cumulative net cash provided by operating activities was $1.70 billion, compared to $1.50 billion in the prior year [9]. Future Outlook - For 2026, revenue growth is projected to be between 2.5% and 4.5%, with the Zacks Consensus Estimate for revenues at $8.41 billion, indicating a 3.1% year-over-year growth [10]. - Adjusted earnings per share guidance for the full year is expected to be in the range of $8.30 to $8.45, while the Zacks Consensus Estimate for adjusted earnings per share is pegged at $8.54 [10]. Market Sentiment - Estimates for Zimmer Biomet have trended downward over the past month, indicating a potential shift in market sentiment [11][13]. - The company currently holds a Zacks Rank 3 (Hold), suggesting an expectation of an in-line return in the coming months [13].